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Background: Macrophages control innate and acquired immunity, but their role in 
severe asthma remains ill-defined. We investigated gene signatures of macrophage 
subtypes in the sputum of 104 asthmatics and 16 healthy volunteers from the 
U-BIOPRED cohort.
Methods: Forty-nine gene signatures (modules) for differentially stimulated mac-
rophages, one to assess lung tissue-resident cells (TR-Mφ) and two for their polariza-
tion (classically and alternatively activated macrophages: M1 and M2, respectively) were 
studied using gene set variation analysis. We calculated enrichment scores (ES) across 
severity and previously identified asthma transcriptome-associated clusters (TACs).
Results: Macrophage numbers were significantly decreased in severe asthma com-
pared to mild-moderate asthma and healthy volunteers. The ES for most modules 
were also significantly reduced in severe asthma except for 3 associated with in-
flammatory responses driven by TNF and Toll-like receptors via NF-κB, eicosanoid 
biosynthesis via the lipoxygenase pathway and IL-2 biosynthesis (all P < .01). Sputum 
macrophage number and the ES for most macrophage signatures were higher in the 
TAC3 group compared to TAC1 and TAC2 asthmatics. However, a high enrichment 
was found in TAC1 for 3 modules showing inflammatory pathways linked to Toll-like 
and TNF receptor activation and arachidonic acid metabolism (P < .001) and in TAC2 
for the inflammasome and interferon signalling pathways (P < .001). Data were vali-
dated in the ADEPT cohort. Module analysis provides additional information com-
pared to conventional M1 and M2 classification. TR-Mφ were enriched in TAC3 and 
associated with mitochondrial function.
Conclusions: Macrophage activation is attenuated in severe granulocytic asthma 
highlighting defective innate immunity except for specific subsets characterized by 
distinct inflammatory pathways.
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1  | INTRODUC TION
Asthma is a heterogeneous disease driven by diverse inflamma-
tory mechanisms, which presents in various clinical forms. Severe 
asthma is a clinically defined subset of asthma that remains partly 
or totally unresponsive to known asthma treatments.1 Both re-
cruited inflammatory and resident airway structural cells partic-
ipate in the inflammatory and remodelling processes associated 
with asthma phenotypes.2 Recently, type-2-related and non–type-
2-related molecular phenotypes or transcriptomic-associated 
clusters (TACs) have been described.3 TACs were derived from 
clustering of differentially expressed genes identified in the spu-
tum of asthmatic patients and provide mechanistic pathways be-
yond eosinophilic subtyping.
Macrophages within the lung play a role in the control of both 
innate and acquired immunity, tissue homeostasis, angiogenesis and 
metabolism.4 Hallmarks of macrophages are their plasticity and di-
versity. Two populations of macrophages coexist in the lung: (a) tis-
sue-resident macrophages (TR-Mφ) that arise during embryogenesis 
are associated with proliferation and defined by Krebs cycle, amino 
acid and fatty acid (FA) metabolic processes and (b) recruited macro-
phages that originate postnatally from circulating monocytes and are 
involved in immune signalling and inflammation and defined by gly-
colysis and arginine metabolism.5 Tissue damage or infection results 
in TR-Mφ activation with production of inflammatory mediators, 
together with monocyte recruitment.4,6 Cytokines drive macro-
phage polarization (diversity) with two classical subtypes according 
to their functional properties: classically activated M1 driven by IFN-
γ, LPS, GM-CSF or TNF-α exposure and alternatively activated M2 
macrophages induced by IL-4, IL-10, IL-13, glucocorticoids or TLR 
ligands.4 While M1 macrophages have pro-inflammatory properties 
and are associated with Th1 responses, M2 macrophages control in-
flammation through the high expression of IL-10 and are involved in 
Th2-mediated immunity.4,7
The role of macrophages in asthma pathogenesis is unclear be-
cause of the limited methods available to characterize them.6 Current 
data suggest that the presence of M1 macrophages is associated 
with disease progression and airway remodelling, M2 macrophages 
are associated with type-2 asthma4,8 and the role of TR-Mφ remains 
unknown. However, human monocyte-derived macrophages stimu-
lated with 28 different stimuli produced 49 distinct transcriptomic 
modules highlighting the spectrum of macrophage diversity.9
We hypothesized that analysis of these 49 macrophage tran-
scriptomic signatures will indicate activation of distinct macrophage 
subsets in severe asthma. We assessed this using gene set variation 
analysis (GSVA) using sputum cells from the U-BIOPRED (Unbiased 
BIOmarkers in PREDiction of respiratory disease outcomes) asthma 
cohort10 with validation in the ADEPT (Airway Disease Endotyping 
for Personalized Therapeutics) cohort.11 This is the first comprehen-
sive analysis of airway macrophage subtypes in asthma.
K E Y W O R D S
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G R A P H I C A L  A B S T R A C T
This study investigates gene signature of macrophage phenotypes in sputum of asthmatic and healthy controls. Several specific macrophage 
subsets identified by gene signatures are highly activated in severe granulocytic asthma and involved distinct inflammatory pathways (eg 
tumour necrosis factor [TNF] and Toll-like receptor [TLR] signalling pathways). Macrophage activation and numbers are reduced in severe 
granulocytic asthma highlighting defective innate immunity.
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Subjects n 61 23 20 16
Age years 53.89 ± 12.14 52.65 ± 11.15 42.05 ± 15.85 38.06 ± 13.27 <.001
Female n (%) 37 (60.66) 12 (52.17) 11 (55) 4 (25) <.001
BMI kg/m2 27.90 ± 5.26 29.40 ± 4.98 25.76 ± 4.96 25.71 ± 2.79 .034
Current smoking n (%) 0 (0) 8 (34.78) 0 (0) 0 (0) <.001
Atopy n (%) 42 (68.85) 13 (56.52) 16 (80) 5 (31.25) <.001
Comorbidities
Allergic rhinitis n (%) 24 (39.34) 7 (30.43) 11 (55) 2 (12.50) .020
Eczema n (%) 17 (27.87) 9 (39.13) 7 (35) 0 (0) .046
Nasal polyposis n (%) 22 (36.07) 8 (34.78) 4 (20) 1 (6.25) .049
Oral corticosteroids daily 22 (36.07) 12 (52.17) 0 (0) NA <.001
Exacerbations number/year 2.41 ± 2.01 2.35 ± 2.59 0.45 ± 0.76 NA <.001
ACQ5 2.26 ± 1.31 2.14 ± 1.20 1.00 ± 0.75 NA <.001
Lung function
FEV1% predicted 61.25 ± 21.66 67.87 ± 18.01 92.45 ± 13.00 105.90 ± 10.29 <.001
FVC % predicted 87.25 ± 18.53 95.38 ± 19.37 108.57 ± 14.32 113.58 ± 10.49 <.001
FEV1/FVC ratio 0.55 ± 0.13 0.59 ± 0.09 0.71 ± 0.08 0.79 ± 0.03 <.001
FeNO ppb 40.84 ± 39.64 27.04 ± 19.67 40.37 ± 33.92 19.71 ± 9.86 <.001
Sputum cells (%)
Eosinophils 13.93 ± 21.12 12.83 ± 15.72 1.82 ± 3.07 0.12 ± 0.25 <.001
Neutrophils 60.09 ± 27.73 55.97 ± 19.65 50.01 ± 25.48 43.16 ± 25.85 .030
Lymphocytes 1.26 ± 1.34 1.39 ± 0.88 1.11 ± 1.17 1.26 ± 1.01 .987
Macrophages 24.69 ± 21.47 29.78 ± 19.49 47.02 ± 24.45 55.45 ± 25.67 <.001
Mast cells 0.03 ± 0.08 0.02 ± 0.08 0.04 ± 0.08 0.01 ± 0.05 .404
Sputum cells count ×103/µL
Total cells 590.51 ± 122.94 602.29 ± 93.99 614.50 ± 91.01 680.47 ± 149.15 .004
Eosinophils 71.03 ± 107.72 69.70 ± 86.61 10.45 ± 17.89 0.63 ± 1.31 <.001
Neutrophils 315.90 ± 149.14 297.91 ± 104.02 270.55 ± 252.50 228.81 ± 140.25 .039
Macrophages 132.36 ± 123.50 158.26 ± 103.48 253.45 ± 133.56 289.13 ± 133.67 <.001
Blood cells ×103/µL
Eosinophils 0.38 ± 0.33 0.30 ± 0.15 0.21 ± 0.11 0.13 ± 0.09 <.001
Neutrophils 5.20 ± 2.35 5.99 ± 2.42 3.69 ± 1.22 3.85 ± 1.55 .009
Serum markers
Total IgE IU/mL 234.14 ± 417.61 377.14 ± 513.62 336.04 ± 861.59 113.66 ± 172.99 .089
Periostin ng/mL 53.01 ± 18.45 51.49 ± 17.94 45.79 ± 10.77 47.33 ± 5.38 .059
IL-13 pg/mL 1.07 ± 1.56 0.63 ± 0.38 0.68 ± 0.44 0.36 ± 0.21 .003
Eotaxin pg/mL 140.84 ± 80.77 109.35 ± 41.20 92.06 ± 45.18 92.19 ± 37.03 .001
TNF-α pg/mL 1.97 ± 0.57 1.96 ± 0.65 1.88 ± 0.79 1.71 ± 0.33 .028
IL-6 pg/mL 1.33 ± 1.22 1.05 ± 0.49 0.83 ± 0.73 0.52 ± 0.26 <.00
IFN-G pg/mL 9.99 ± 9 7.84 ± 7.49 9.81 ± 7.50 6.95 ± 3.86 0.057
MCP1 pg/mL 122.18 ± 38.02 113.25 ± 42.32 92.02 ± 31.14 85.16 ± 20.19 <.001
CCL18 pg/mL 217.04 ± 125.40 193.78 ± 70.60 148.41 ± 109.45 107.20 ± 58.76 <.001
CRP mg/L 8.31 ± 16.18 3.17 ± 3.01 2.04 ± 2.74 0.89 ± 0.73 <.001
Note: Data are presented in mean ± SD.
Abbreviations: ACQ5, Asthma Control Questionnaire 5; BMI, body mass index; CCL18, C-C motif chemokine ligand 18; CRP, C-reactive 
protein; FeNO, fractional exhaled nitric oxide; FEV1, forced expiratory volume in 1s; FVC, forced vital capacity; IFN-G, interferon gamma; Ig E, 
immunoglobulin E; IL-13, interleukin 13; IL-6, interleukin 6; MCP1, monocyte chemoattractant protein 1; NA, not applicable; TNF-α, tumour necrosis 
factor.
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TA B L E  2   Description of macrophage modules according to stimuli and corresponding pathways and functions (KEGG 2019, Reactome 
2016, WikiPathways Humans 2019)
Module Stimuli Function
1 Fatty acids (LA, OA) Glycolysis/gluconeogenesis, metabolism of carbohydrates, biosynthesis of amino acids
2 Fatty acids (LA) Methionine de novo and salvage pathway, cysteine and methionine metabolism, ribosome biogenesis
3 M1 (LPS, LPS + IFN-γ) Vesicle biogenesis by lysosome and vesicle-mediated transport, development of macrophages and 
dentritic cells, IL-6 signalling pathway
4 Fatty acids (OA, PA) Mitochondrial fatty acid beta-oxidation of saturated fatty acids, ligand-independent caspase 
activation, TRAF6-mediated activation in TLR7/8 or 9, regulation of neutrophil-mediated immunity 
and degranulation
5 Fatty acids (PA, OA, LA) Protein processing in endoplasmic reticulum, base excision repair, cellular response to sterol depletion
6 Fatty acids (OA, LA, PA) Carbohydrate metabolism, negative regulation of leucocyte leucocytes degranulation, positive 
regulation of IL-8 secretion
7 M1 (IFN-γ) Interferon-signalling pathways, antiviral mechanism by interferon stimulated genes, IL-10 anti-
inflammatory signalling pathway
8 M1 (IFN-γ, IFN-γ + TNF-α) Phagosome, type II interferon signalling pathway (IFN-γ), Toll-like receptor signalling pathway
9 M1 (IFN-γ + TNF-α, IFN-γ) Aminoacyl-tRNA biosynthesis, signalling by WNT, positive regulation of TNF-mediated signalling 
pathway
10 M2 (IL-4, IL-10) Ribosome, electron transport chain in mitochondria, interferon type I signalling pathway
11 M2 (IL-4, IL-13) Modulation of viral transcription, ribosome
12 M2 (IL-4) Galactose, fructose, mannose metabolism, target of rapamycin (mTOR) signalling pathway, regulation 
of TP53 activity
13 M2 (IL-4, IL-13) Oxidative phosphorylation and citrate cycle in mitochondria, regulation of leucocyte activation, Toll-
like receptor 2 signalling pathway, positive regulation of TNF-α biosynthesis
14 
(SAsm)
M2 (IL-4, IL-13) Phagosome-lysosome fusion (r = .60, P < .001)
15 M2 (IL-4, IL-13) Inflammatory response, neutrophil chemotaxis (r = .55, P < .001)
Toll-like receptors (1, 2, 4, 6) pathway (r = .67, P < .001)
IL-17 signalling pathway (r = .34, P < .001)
Arachidonic acid metabolism (r = .28, P = .002)
16 Fatty acids (PA, SA) Cholesterol metabolism, PPAR signalling pathway, IL-1β induced activation of NF-κB pathway
17 Fatty acids (PA, SA) Glycosphingolipid biosynthesis
18 Fatty acids (PA, LiA, OA) Proteasome, regulation of apoptosis
19 Fatty acids (PA, SA, OA) Proteasome, phagosome
20 Fatty acids (PA, SA, LiA) Positive regulation of cholesterol storage, positive regulation of T-helper cell differentiation, IL-10 anti-
inflammatory signalling pathway
21 Fatty acids (PA, SA) Eicosanoid biosynthetic process on the lipoxygenase pathway, Unsaturated fatty acids biosynthesis 
(r = .53, P < .001)
22 Fatty acids (OA, LA, LiA) Cell cycle, mitosis
23 Fatty acids (OA, LA, LiA) Methylation pathway, mitochondrial complex I assembly model OXPHOS system, IL-1β induced 
activation of NF-κB pathway
24 Fatty acids (OA, LA, LiA) rRNA metabolic process, PI3K-AKT-mTOR signalling pathway, Mitochondrial translation
25 Fatty acids (PA, LiA, SA) Golgi vesicle transport, protein transport
26 Fatty acids (LiA, OA, PA) RNA binding, NF-κB binding
27 Fatty acids (LA, LA, SA) Regulation of steroid and cholesterol biosynthesis
28 Fatty acids (OA, LiA) Phagosome-lysosome fusion, regulation of Toll-like receptor 9 signalling pathway, positive regulation 
of granulocyte differentiation
29 Others (TPP, TPP + IFN) NF-κB signalling pathway (r = .62, P < .001),
TNF-α signalling pathway (r = .50, P < .001),
Positive regulation of IL-2 biosynthetic process (r = .66, P < .001)
30 Others (TPP, TPP + IFN) Positive regulation of acute inflammatory response, regulation of chemokines production, cytokine-
cytokine receptor interaction and neutrophil-mediated immunity
(Continues)
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2  | METHODS
2.1 | Study population and design
We studied data from participants of the U-BIOPRED adult cohort10 
who underwent sputum cell transcriptomic analysis.3 This included 
104 asthmatics: mild-moderate asthma (n = 20), nonsmoking severe 
asthmatics (n = 61) and current or ex-smokers with severe asthma 
(n = 23), and 16 healthy volunteers (Table 1). All participants gave 
written informed consent. For the asthmatic patients, the analyses 
were done also according to the presence of airflow limitation de-
fined as FEV1/FVC < 0.70 and FEV1 < 75% of predicted.3
A description of the analytical plan is provided in Figure S1.
2.2 | Microarray analysis of sputum transcriptomes
Sputum induction12 and transcriptomic analysis has been de-
scribed previously.13 In brief, sputum cells were obtained from 
plugs obtained following inhalation of hypertonic saline. Gene 
expression profiling was performed on extracted RNA using mi-
croarrays.3 A comparison of sputum gene expression profiles from 
asthmatics with high (≥1.5%) or low (<1.5%) sputum eosinophilia 
and the healthy volunteer group identified 508 differentially 
expressed genes. Batch/technical effects, age, sex and admin-
istration of oral corticosteroid were adjusted for as covariates. 
Unsupervised hierarchical clustering based on Euclidean distance 
on these 508 genes identified 3 transcriptomic-associated clus-
ters (TACs): TAC1 was associated with Th2 inflammation, sputum 
eosinophilia, more severe asthma, high rate oral corticosteroid 
dependency, frequent exacerbations and severe airflow obstruc-
tion, TAC2 with IFN-γ, TNF-α and inflammasome-signalling path-
ways, sputum neutrophilia, high prevalence of eczema and serum 
C-reactive protein levels and TAC3 with paucigranulocytic inflam-
mation, metabolic pathways and better preserved lung function.3 
These groups are considered as reflective of different molecular 
phenotypes of asthma in the U-BIOPRED cohort and were used 
in our analyses.
Module Stimuli Function
31 Fatty acids (PA, SA) Toll-like receptor signalling pathway, TNF-α signalling pathway, IL-1β signalling pathway
32 Others (TPP, TPP + IFN) Fatty acids, triacylglycerol and ketone metabolism, regulation of neutrophil-mediated immunity and 
degranulation, regulation of IL-1β production and NK cell mediated cytotoxicity
33 M1 (LPS) IL-2 signalling pathway, T-cell antigen receptor (TCR) pathway, intrinsic apoptosis in response to 
oxidative stress
34 Others (TPP, TPP + IFN) Oxidative phosphorylation (OXPHOS) in mitochondria, modulation of TGFβ signalling pathway, 
positive regulation of adaptive immune response
35 M1 (IFN-γ + TNF-α) OXPHOS system in mitochondria (electron transport)
36 Others (TPP) Staphylococcus aureus infection, phagosome
37 M2 (IL-4) Proteasome degradation, inositol phosphate metabolic process
38 Others (TPP, TPP + IFN) Positive regulation of microtubule activity, snRNA metabolic process
39 Others (TPP, TPP + IFN) Glycolysis/gluconeogenesis, amino acid metabolism, steroid catabolic process
40 Others (TPP, TPP + IFN) Ribosome biogenesis, DNA replication
41 Others (GC) Sphingolipid metabolic pathway, apoptotic cell clearance, insulin-like growth factor (IGF1)-Akt 
signalling pathway
42 Others (GC) Lysosome, Toll-like receptor pathway, carbohydrate digestion and absorption
43 Others (GC, HDL) Complement and coagulation cascades, superoxide metabolic process, regulation of lymphocyte 
activation
44 Fatty acids (OA) TGFβ-signalling pathway, regulation of IL-10 secretion, mitochondrial DNA metabolic process
45 M2 (IL-4, IL-10, IL-13) NF-κB signalling pathway, TNF signalling pathway, fatty acids biosynthesis
46 M2 (IL-4, PGE2) Antigen processing and presentation via MHC class II, Th-17 differentiation, allograft rejection
47 M2 (IL-4, PGE2) DNA damage induced protein phosphorylation, positive regulation of extracellular matrix assembly, 
TP53 network
48 M2 (IL-4, IL-13, PGE2) Ions homeostasis, Toll-like receptor signalling pathway, angiogenesis
49 Unstimulated Negative regulation of acute inflammatory response, negative regulation by host of viral process, 
intrinsic apoptotic signalling pathway in response to oxidative stress
Note: Modules enriched in severe asthma are highlighted in BOLD with r and P values indicated.
Abbreviations: IFN, interferon; IL-13, interleukin 13; IL-17, interleukin 17; IL-2, interleukin 2; IL-4, interleukin 4; M2, alternatively polarized 
macrophage; NF-κB, nuclear-factor kappa B; PA, palmitic acid; SA, stearic acid; SAsm, severe asthma smokers and ex-smokers; TNF, tumour necrosis 
factor alpha; TPP, tumour necrosis factor alpha + prostaglandin E2 + Toll-like receptor 2 ligand.
TA B L E  2   (Continued)
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2.3 | Gene set variation analysis (GSVA)
Gene set variation analysis is a gene set enrichment method 
that estimates the variation in a pathway activity across a sam-
ple population in an unsupervised manner. It is used to detect 
changes in pathway or gene signature activity over a sample 
population and indicates differences within populations and 
between groups of subjects.13,14 GSVA calculates sample-wise 
enrichment scores (ES) across the whole data set with a range 
from −1 to +1.
2.4 | Macrophage signatures
Forty-nine distinct modules previously published9 derived from 
28 distinct treatments (eg IFN-γ, IL-4, IL-10, LPS, TNF-α, IL-13, 
free fatty acids, high-density lipoprotein, prostaglandin E2, cor-
ticosteroids or various association of these stimuli), contain-
ing 27 to 884 genes per module, were manually curated in R 
Bioconductor (R Foundation for Statistical Computing, Vienna, 
Austria) to analyse macrophage signatures according to asthma 
severity, TACs and airflow limitation. Validated M1 and M2 sig-
natures (stimulated by IFN-γ + LPS or TNF-α, and IL-4 + IL-13, 
respectively)15 and a TR-Mφ signature adapted from a murine 
model16 were also examined (Table S1). Although some of the 
stimuli were the same, the module genes were often different 
reflecting altered cellular states resulting from distinct pathways 
characterizing the modules and highlighting macrophage hetero-
geneity (Table 2). Validation of the module signatures was per-
formed using GSE90010 comparing purified MDMs populations 
against alveolar macrophages (AM) from idiopathic pulmonary 
fibrosis (IPF) patients (Table S2).
2.5 | Pathway analysis
The functions and pathways for each gene signature were assessed 
using KEGG 2019, WikiPathways 2019 and Reactome 2016 data-
bases within Enrichr17 (Table 2), and for the pooled activated genes 
by STRING (www.strin g-db.org).
2.6 | Statistical analysis
A linear model for microarray data (Bioconductor R package limma) 
with a false discovery rate (FDR) correction was used for differential 
gene expression analysis and recursive partitioning (party package in 
R) for decision tree learning. An FDR ≤ 0.05 was considered statisti-
cally significant. The ES was calculated for each gene set for each 
subject. ANOVA was used to analyse ES differences between group 
means, and the Student t test was applied to compare ES differences 
between two means.
3  | RESULTS
3.1 | Macrophage signatures according asthma 
severity
In initial analysis to determine whether macrophage modules were 
selective for macrophages, we demonstrated that 41/49 module 
signatures were similarly enriched in AM and MDMs from healthy 
volunteers and IPF patients (Table S2). Two of the signatures were 
significantly decreased while 6 of the signatures were significantly 
enriched in AM compared with monocyte-derived macrophages.
The total number and percentage of macrophages in sputum was 
reduced by ~50% in severe asthma but not in mild-moderate asthma 
(Table 1). However, not all macrophages subtypes were decreased 
according to GSVA analysis. Figure 1 represents the ES values for 
the 49 macrophage modules showing a significant reduction in the 
ES for most macrophage modules in severe asthma vs healthy vol-
unteers. The ES for modules 7, 8, 9, 20, 27, 30-32, 36 and 45 which 
are associated with antiviral activity by IFN-stimulated genes, pha-
gosome activation and FA metabolism were similar between asthma 
and healthy volunteers (Figure 1). The most significant biological 
pathways and functions ascribed to each module are summarized 
in Table 2 with the respective r and P values for modules 15, 21 and 
29, which were significantly enriched in severe asthma, also being 
shown.
Representative dot plots of the GSVA ES for selected mod-
ules are shown in Figure 2 to indicate the range of enrichment 
within subject groups. In contrast to the reduced numbers of mac-
rophages seen in severe asthma compared with mild-moderate 
asthma and healthy volunteers, modules 15, 21, respectively 29 
were significantly enriched in severe asthma vs mild-moderate 
asthma and healthy volunteers (Figures 1 and 2A,B). These mod-
ules reflect IL-4/IL-13 activation (module 15), FA (stearic and pal-
mitic acid)-stimulated macrophages (module 21) and macrophages 
associated with chronic inflammation (CI-Mφ) (module 29, stimu-
lated by TPP: TNF-α + PGE2 + the TLR2-ligand Pam3CSK4).9 Their 
genes are involved in innate inflammatory responses, eicosanoid 
biosynthesis via the 5-LOX pathway, T-cell differentiation through 
the regulation of IL-2 production and IL-17 signalling (Table 2). 
Only module 14, associated with the phago-lysosome fusion, lym-
phocyte migration and fat cell proliferation, was significantly en-
riched in severe asthma smokers vs severe asthma nonsmokers 
(P = .02). In contrast, representative GSVA plots of the enrichment 
of module 18 (FA) show significant down-regulation in severe 
asthma compared to mild-moderate asthma and healthy volun-
teers (Figure 2C). There were no significant differences in the 
enrichment of TR-Mφ, M1 or M214,15 or in sputum across asthma 
severity using GSVA (Figure 2D-F).
These data highlight the plasticity of macrophages in that mac-
rophage subtypes or states distinguished by WGCNA modules 
provide additional signals compared to validated M1 and M2 sig-
natures. Overall, the data indicate reduced macrophage numbers 
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and activation status in severe asthma compared to mild-moderate 
asthma and healthy volunteers suggesting an attenuated innate im-
mune response in these patients. However, there is a limited sub-
type-specific activation of macrophages in severe asthma compared 
to mild-moderate asthma.
3.2 | Macrophage enrichment according to sputum 
granulocytes
When the sputum transcriptome was assessed according to TAC sig-
nature as representative of sputum asthma molecular phenotypes, 
there was a significant decrease of the macrophage absolute cell 
count in TAC1 (141.53 × 103/µL) compared to TAC2 (195.46 × 103/
µL) and TAC3 (202.88 × 103/µL) subjects (P = .009 and P = .003, re-
spectively) (Table S3) without significant difference between TAC2 
and TAC3 (P = .705). The ES of most (35/49) macrophage modules 
were increased in TAC3 compared to TAC1 and TAC2 (Figure 3) 
while only 4 modules being significantly enriched in TAC1 compared 
to TAC3. These were module 15 implicated in positive regulation of 
inflammatory response by neutrophil chemotaxis, arachidonic acid 
metabolism, activation of TLR and IL-17 signalling pathways; module 
21 associated with eicosanoids (via 5-LOX pathway) and unsaturated 
FA biosynthesis; module 27 including genes that regulate steroid and 
cholesterol biosynthesis and module 29 characterized by genes en-
coding TNF-α and NF-κB pathways and positive regulation of IL-2 
production.
In TAC2, the modules 15, 27 and 29 are also highly enriched 
compared to TAC3 as well the modules 7-8 associated with an-
tiviral activity via the IFN-γ pathway; module 20 with IL-10 sig-
nalling pathway and Th-cell differentiation; modules 30-32 with 
the inflammatory response with neutrophil chemotaxis involving 
F I G U R E  1   Heat map of enrichment scores (ES) for the 49 macrophage activation modules according to clinical category. GC, 
glucocorticoids; HDL, high-density lipoprotein; HV, healthy nonsmoking controls; IFN-γ, interferon γ; IL-10, interleukin 10; IL-13, interleukin 
13; IL4, interleukin 4; LA, lauric acid; LiA, linoleic acid; LPS, bacterial lipopolysaccharide; MMA, mild/moderate asthma; OA, oleic acid; PA, 
palmitic acid; PGE2, prostaglandin E2; SA, stearic acid; SAns, severe asthma nonsmokers; SAsm, severe asthma smokers; TNF-α, tumour 
necrosis factor; TPP, TNF-α + prostaglandin E2 + Toll-like receptor 2 ligand. Where no value is given the results were not significant
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TLR, inflammasome and TNF-α signalling pathways; and modules 
47 and 49 with mitochondrial process and apoptosis secondary to 
the oxidative stress.
We observed an enrichment of module 15 in both TAC1 (eosino-
philic) and TAC2 (neutrophilic) groups. However, other M2-related sig-
natures such as module 47 (IL-4, PGE2) was enriched in TAC2 compared 
to TAC1 and module 48 (IL-4, IL-13 and PGE2) was enriched in TAC3. This 
suggests that these M2-related subtypes reflect the local inflammatory 
milieu and that not all M2 cells are the same. In contrast, TAC2 was more 
enriched with macrophage signatures encoding M1-like modules (mod-
ules 7 and 8) and macrophages stimulated by either FAs (modules 20, 
21, 27 and 31) or TPP (modules 29, 30 and 32) (Figure 3). This indicates 
either the presence of low-grade sub-clinical infection or of a skewed 
immune response following previous infection since no overt infection 
had been reported in the 3 months prior to sputum induction.
Representative dot plots of the GSVA ES for selected modules indi-
cate the range of enrichment within subject groups. Module 21 (FA) was 
significantly down-regulated in TAC2 compared with TAC1 and TAC3 
(Figure 4A), module 29 (TPP) was significantly enriched in TAC1 and TAC2 
compared with TAC3 (Figure 4B) while module 30 (a different TPP mod-
ule) (Figure 4C) was enriched in TAC2 compared to both TAC1 and TAC3.
In contrast, the TR-Mφ macrophage signature was signifi-
cantly enriched in the TAC3 module (Figure 4D), the M1 validated 
signature14 in TAC2 (Figure 4E) and the M2 validated signature14 was 
significantly reduced in TAC2 (Figure 4F). The genes from TR-Mφ 
signature15 encode proteins involved in metabolic process, tissue 
homeostasis and immunity (Table S4).16,18
The M1 validated signature was highly correlated with sputum neu-
trophilia (TAC2), with T naïve cells and with pathways involved in in-
flammation (NF-κB, TNF, TLR and inflammasome pathways) (Table S5). 
The M2-validated signature was significantly correlated with TAC3 
and the TR-Mφ signature with TAC3, to phago-lysosome activity and 
to oxidative phosphorylation (OXPHOS) (Table S5). More detailed in-
formation about TR-Mφ functions is provided in the (Table S6).
Overall, these data suggest that patients with severe granulocytic 
asthma have a reduced innate immune response as indicated by the 
reduced enrichment of most macrophage subsets. However, a select 
number of macrophage modules/subsets are enhanced in TAC1 and 
TAC2. These results were validated by the analyses on the ADEPT co-
hort which present similar characteristics in terms of severity and in-
flammatory clusters as U-BIOPRED (2) and Table S7. Figure S2 shows 
a heat map of the macrophage module ES according to sputum gran-
ulocytes. In summary, these data highlighted the relative enrichment 
of most modules in paucigranulocytic and healthy volunteers with 
the same modules enriched in neutrophilic (modules 8, 27, 30-31 and 
49) (all P < .001) and eosinophilic (modules 15, 21 and 29) (all P ≤ .03) 
F I G U R E  2   Representative analysis of selected macrophage module enrichment scores (ES) according asthma severity. Gene set variation 
analysis (GSVA) plots of individual subject ES for (A) module 15—IL-4- and IL-13-stimulated, (B) module 29—TPP- and TPP + IFN-stimulated 
and (C) module 18—PA-, LiA- and OA-stimulated. The ES for tissue-resident macrophages (D, TR-Mφ), classically activated macrophages (E, 
M1 from Becker) and alternatively activated macrophages (F, M2 from Becker) are also shown. HV, healthy volunteers; IFN-γ, interferon γ; IL-
13, interleukin 13; IL-4, interleukin 4; LiA, linoleic acid; MMA, mild/moderate asthma; OA, oleic acid; PA, palmitic acid; SAns, severe asthma 
nonsmokers; SAsm, severe asthma smokers and ex-smokers; TPP, TNF-α + prostaglandin E2 + Toll-like receptor 2 ligand (Pam3CSK4). 
*P < .001; #P < .05; P = NS (NS, nonsignificant)
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asthma as described using TAC analysis in the U-BIOPRED cohort. 
The same modules as in TAC3 were decreased in ES in the ADEPT 
paucigranulocytic group (modules 8, 15, 27, 29, 30 and 31).
3.3 | Macrophages signatures in airflow obstruction
The same modules 15, 21 and 29 that were overexpressed in severe 
asthma and associated with inflammation driven by innate immunity were 
correlated with airflow obstruction (Figure S3). In contrast, most M1- and 
M2-related modules were inversely associated with obstruction. The 
TR-Mφ signature did not correlate with airflow obstruction (Figure S4).
3.4 | Drivers of macrophage activation according to 
severity and TAC characterization
A number of different macrophage signatures were enriched in se-
vere asthma and according to TAC categorization. Examination of 
the specific mediators associated with each macrophage module 
FI G U R E 3 Heat map of enrichment scores (ES) for the 49 macrophage activation modules according to transcriptomic-associated cluster (TAC1, 
TAC2 or TAC3). GC, glucocorticoids; HDL, high-density lipoprotein; IFN-γ, interferon γ; IL-10, interleukin 10; IL-13, interleukin 13; IL-4, interleukin 4; 
LA, lauric acid; LiA, linoleic acid; LPS, bacterial lipopolysaccharide; OA, oleic acid; PA, palmitic acid; PGE2, prostaglandin E2; SA, stearic acid; TNF-α, 
tumour necrosis factor; TPP, TNF-α + prostaglandin E2 + Toll-like receptor 2 ligand. Where no value is given, the results were not significant
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according to TAC does not provide clear evidence for the criti-
cal factors that may underpin macrophage activation in each TAC 
(Figure S5). We therefore pooled the activated genes within each 
module9 for severe asthma and for each TAC and examined the 
pathways and gene ontology terms associated with these groups 
to determine whether specific pathways or driver mechanisms 
were present.
Combining the macrophage gene signatures enriched in severe 
asthma and performing PPI network analysis identified several path-
ways important in severe asthma including innate immunity, leuco-
cyte activation, neutrophil degranulation, IL-4/IL-13 signalling, TLR 
and IL-17 signalling and leukotriene synthesis (Table 3, Figure 5). The 
pathways associated with macrophages activated in TAC1 patients 
highlighted cholesterol and steroid biosynthesis pathways along with 
pathways associated with Th2 activation and defence responses 
(Figure S6, Table S8). In addition, the PPI networks identified as being 
preferentially activated in TAC2 patients included immune and in-
flammatory pathways linked to inflammasome and neutrophil acti-
vation (Figure S7, Table S9). Finally, TAC3-associated PPI pathways 
reflect metabolic and mitochondrial function in addition to cytokine 
signalling and viral response pathways (Figure S8, Table S10). These 
data expand the pathways associated with TACs described previ-
ously and highlight the importance of macrophages in severe asthma 
pathophysiology.
4  | DISCUSSION
Sputum macrophage numbers are reduced in severe asthma com-
pared to mild-moderate asthma and healthy volunteers. GSVA analy-
sis of macrophage signatures demonstrated decreased ES in severe 
asthma compared to mild-moderate asthma and healthy volunteers 
except for CI-Mφ activated by FA and an M2-like module. Module 
enrichment occurs in purified AM populations validating the use of 
signatures to give additional insight compared with that obtained 
using the classic M1 and M2 classification. Glucocorticoid/high-
density lipoprotein-exposed and M1-like macrophages were en-
riched in the severe asthma smokers vs severe asthma nonsmokers. 
Sputum macrophage numbers are significantly decreased in TAC1 
compared to TAC2 and TAC3 groups and the ESs for most signatures 
were greater in TAC3 compared to TAC1 and TAC2 subjects. TR-Mφ 
were enriched in TAC3 and associated with mitochondrial function. 
Overall, macrophage activation is attenuated in severe granulocytic 
asthma except for enrichment of specific macrophage subsets in-
dicative of distinct inflammatory pathways.
NF-κB activation is common to both modules 15 and 29 sug-
gesting its activation in severe TAC1 and TAC2 asthmatics. NF-κB 
regulates inflammatory and innate immune gene expression18 during 
asthma pathogenesis.19 Module 15 (an M2 subtype) is also associ-
ated with TLR pathway activation. Most TLRs are expressed on 
F I G U R E  4   Representative analysis of selected macrophage module enrichment scores (ES) according to transcriptomic clusters (TACs). 
Gene set variation analysis (GSVA) plots of individual subject ES for (A) module 21—PA- and SA-stimulated, (B) module 29—TPP- and 
TPP + IFN-stimulated and (C) module 30—TPP- and TPP + IFN-stimulated. The ES for tissue-resident macrophages (D, TR-Mφ), classically 
activated macrophages (E, M1 from Becker) and alternatively activated macrophages (F, M2 from Becker) are also shown. HV, healthy 
volunteers; IFN-γ, interferon γ; MMA, mild/moderate asthma; PA, palmitic acid; SA, stearic acid; SAns, severe asthma nonsmokers; SAsm, 
severe asthma smokers and ex-smokers; TPP, TNF-α + prostaglandin E2 + Toll-like receptor 2 ligand (Pam3CSK4). *P < .001; #P < .05. 
Where no value is given, the results were not significant
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macrophages and their activation induces inflammatory cytokines 
involved in the recruitment of T cells (CCL3 and CCL4), monocytes 
(CCL1) and neutrophils (CXCL1 and CXCL8).20-23 Module 29 is as-
sociated with chronic inflammation and TNF pathway activation.9 
Macrophages possess several TNF receptors including TNFR1 and 
2, TL1A, OX40, 4-1BB, CD30, CD40, LIGHTR, LTβR, GITR, BAFF, 
APRIL and TWEAK which all stimulate NF-κB.24,25 In addition, OX40 
stimulation promotes T-cell proliferation and survival26,27 by the reg-
ulation of IL-2 production.28
The third module enriched in severe asthma is module 21 that 
is associated with eicosanoids biosynthesis via the 5-LOX pathway. 
These macrophages are stimulated by palmitic acid, a pro-inflamma-
tory factor for monocytes and associated with increased mitochon-
drial ROS production.29 CysLT promotes Th2 polarization, activation 
of eosinophils (confirmed by the high ES in TAC1) and collagen pro-
duction by fibrocytes30 which could explain the association with air-
flow limitation found in the present study.
The most significant difference between severe asthma smokers 
and severe asthma nonsmokers in our analysis is the high enrichment 
of module 14 in smoking severe asthmatics, which is involved in pha-
go-lysosome fusion and lymphocyte migration. In mice, nicotine in-
hibits phagosome formation in infected macrophages and induces 
the production of TGF-β by regulatory T cells.31
Modules 15, 21 and 29 were enriched in both severe asthma and 
TAC1 subjects reflecting those with severe eosinophilic T2 asthma. 
Module 15 represents a subset or state of M2 macrophages stimu-
lated by IL-4/IL-13 which secrete chemokines including CCL18 and 
CCL24 (eotaxin 2) recognized to promote eosinophil infiltration.3,4 
According to the specific stimuli, M2 macrophages are divided in 
4 subpopulations: M2a induced by IL4/IL13 which activate Th2 
responses; M2b stimulated by LPS or IL-1R ligand with an immu-
noregulator effect and favoured by Th2 response, increasing the 
production of IL-10; M2c prompted by glucocorticoids or IL-10 in-
volved in the inflammation resolution and tissue remodelling (pro-
duction of TGFβ).4,7
Even though the M2a state seems to be particularly involved 
in severe asthma and TAC1, this does not preclude a downstream 
cascade linking with M2b activation. This may explain the associ-
ation of the module 15 with the Toll-like receptor signalling path-
way. In contrast with TAC1, all subsets of M2 macrophages are 
enriched in TAC3 and involved in metabolic processes (modules 
10-14 and 45), homeostasis (modules 47-48), inflammatory resolu-
tion by stimulating phagocytosis, antigen processing and immuno-
regulation (modules 14 and 46). These results reflect the complex 
activation state of sputum macrophages in asthma in response 
to distinct stimuli and their high transcriptional and functional 
diversity.
TAC2 subjects were enriched for macrophage modules involved 
pathogen responses including M1 macrophages. IFN-γ- and LPS-
stimulated M1 macrophages enable phagocytosis of viral/bacterial 
antigens by cross-presentation via MHC class I,32 inflammasome and 
TNF-α activation24,33 and neutrophilic airway inflammation.34 Other 
modules up-regulated in TAC2 indicate the importance of Th17 
(modules 15 and 20) and NK cells (module 32).33,35,36 Taken together, 
these data highlight the heterogeneity of sputum macrophages and 
that modules identify greater differences than consensus M1 and 
M2 signatures.
Data concerning the role of TR-Mφ in severe asthma are lack-
ing. We show no significant change in TR-Mφ enrichment accord-
ing to severity but elevated enrichment in TAC3 subjects. Most of 
the genes within the TR-Mφ signature are involved in mitochondrial 
function (TOMM20, RAC1, NDUFA4, CAD, SIRPA, APOA1BP), lipid 
metabolism, tissue homeostasis and apoptosis but some play roles 
in anti-infectious defence via TNF-α (TNF), TLR (CD36) and inflam-
masome (SIGLEC1) pathways.37 During early inflammation, TR-Mφ 
could switch from M2 (associated with OXPHOS) to M1 polariza-
tion with enhanced glycolysis to rapidly obtain the energy needed 
for migration, ROS and pro-inflammatory cytokines production 
(via NF-κB activation) and phagocytosis.29 Conversely, the reso-




Innate immune system Reactome: HSA-168249 <.001
Regulation of cellular response to 
stimulus
GO: 0048583 <.001
Inflammatory response GO: 0006954 <.001
Leucocyte activation involved in immune 
response
GO: 0002366 <.001
Neutrophil degranulation Reactome: HSA-6798695 <.001
Interleukin-4 and interleukin-13 signalling Reactome: HSA-6785807 <.001
NF-κB signalling KEGG:04064 .004
Toll-like receptor cascades Reactome: HSA-168898 .015
IL-17 signalling KEGG: 04657 .016
Synthesis of leukotrienes Reactome: HSA-2142691 .028
Abbreviation: FDR, false discovery rate.
TA B L E  3   Pathways involved in 
macrophage activation in severe asthma 
compared to mild-moderate asthma 
and healthy controls using PPI network 
analysis (String db)
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phosphatidylserine from apoptotic membranes and CD36 with to 
elicit mitochondrial biogenesis, arginase expression and return to 
an M2 phenotype.29 The dynamic differentiation of macrophages in 
response to environmental signals is highly dependent on NF-κB ac-
tivation and mitochondrial function with increased expression of nu-
merous pro-inflammatory gene characteristic of M1 during the early 
phase of inflammation while the M2 subtype, predominant in the 
later phase of inflammation, have reduced inflammatory capacity.4
The heterogeneous population of airway macrophages are the 
primary cell type to encounter airborne pathogens.38 Our data indi-
cate that in mild-moderate asthma these cells are in a state of pre-
paredness despite ongoing treatment with inhaled corticosteroids 
but that is not the case in patients with severe disease. Previous 
evidence has highlighted a defect in BAL macrophage and mono-
cyte-derived macrophage phagocytosis in severe asthma.39-41This 
has been reported as being associated with enhanced expression 
of PGE2,39 reduced IL-10 expression42 or the persistent presence of 
viral infection.43
The importance of macrophages in mediating asthmatic inflam-
mation is becoming increasingly clear.38 In mice, pharmacological 
suppression of alternatively activated YM1 + M2 macrophages 
using the galactin-3 pathway inhibitor cynaropicrin resulted in re-
duced eosinophilic lung inflammation and less collagen deposition 
around airways and a shift towards neutrophilic inflammation and 
worse lung function.44These data revealed an important role for M2 
macrophages generally in airway remodelling and the role of spe-
cific M2-like macrophages associated in airway remodelling and AHR 
should be further studied.
This is the first study using gene signatures to extensively analyse 
the enrichment and activation of macrophage subtypes in asthma 
according to severity, molecular phenotype and the presence of 
airflow limitation. To the best of our knowledge, it is the first time 
that the enrichment of TR-Mφ has been analysed in asthma where 
it plays a more important role in the paucigranulocytic inflammatory 
phenotype. Another strength of this study is the relatively large 
data set, the validation in another severe asthma cohort (ADEPT) 
F I G U R E  5   Protein-protein interaction (PPI) network analysis of module genes significantly enriched in macrophages activated in severe 
asthma compared to mild-moderate asthma and healthy controls. Pink: arachidonic acid metabolism; light blue: leucocyte activation and 
neutrophil degranulation; green: IL-4 and IL-13 signalling; dark blue: NF-κB signalling; light brown: cellular response to stimuli; red: immune 
system; and yellow: Toll-like receptor cascades. All genes in each module that was differentially expressed were pooled and used in this 
analysis
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and the relative accessibility of the sputum compartment for future 
comparative analysis. Nevertheless, there are several limitations to 
the study including the failure to obtain functional data from these 
macrophage modules and the need to isolate or define these mac-
rophage subtypes using another approach such as cell sorting. It is 
possible that the results may reflect, at least in part, the varying pro-
portional make-up of the immune cells present across the various 
subgroup comparisons, and future studies should use single cell se-
quencing or other approaches to address this. Furthermore, analysis 
of BAL and tissue macrophages may provide additional insights in 
the pathogenesis of severe asthma.
In summary, macrophage numbers and activation status are 
generally decreased in severe asthma suggesting an innate immune 
defect in this population. Enrichment was found only in three mod-
ules involved in the regulation of inflammatory response by TLR/
TNF/NF-κB activation, IL-2 production and leukotriene biosynthesis. 
M1 macrophages were highly expressed in TAC2 and correlate with 
sputum neutrophilia, inflammasome, IFN, TNF and TLR pathways in 
contrast to M2 which were more highly expressed in TAC1 and TAC3 
and correlated with metabolic process and eicosanoids biosynthe-
sis. TR-Mφ were predominantly associated with paucigranulocytic 
asthma. Understanding the functional diversity of macrophages and 
the modulation of their phenotypes in asthma might provide us a 
great opportunity for designing novel and more effective therapeutic 
strategies.
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